Circulating Tumor Cells Market Size, Share & Growth Analysis Report, 2024-2032
Circulating Tumor Cells Market Size, Share & Growth Analysis Report, 2024-2032

Circulating Tumor Cells Market Share, Size, Trends, Industry Analysis Report, By Technology; By Application; By Product (Kits & Reagents, Blood Collection Tubes, Devices or Systems); By Specimen; By Region; Segment Forecast, 2024 - 2032

  • Published Date:Jan-2024
  • Pages: 118
  • Format: PDF
  • Report ID: PM1814
  • Base Year: 2023
  • Historical Data: 2019-2022

Report Outlook

The global Circulating Tumor Cells market was valued at USD 6312.4 million in 2023 and is expected to grow at a CAGR of 13.70% during the forecast period.

The circulating tumor cells (CTCs) market is a rapidly growing sector in cancer diagnostics and personalized medicine. CTCs are cancer cells detached from the primary tumor and entered the bloodstream, allowing them to potentially spread to other parts of the body and form secondary tumors, known as metastases. The ability to detect and analyze CTCs provides valuable insights into cancer progression, monitoring treatment effectiveness, and predicting patient outcomes.

Circulating Tumor Cells Market Size

To Understand More About this Research : Request a Free Sample Report

Cancer is growing worldwide, increasing the demand for effective diagnostic tools. CTCs offer a non-invasive alternative to traditional tissue biopsies, providing real-time information about the tumor's characteristics and genetic mutations. This allows oncologists to make more informed treatment decisions and personalize therapies for individual patients.

Advancements in technology and the development of innovative platforms have also contributed to the growth of the CTCs market. Various methods, such as immunomagnetic separation, microfluidics, and image-based detection systems, have been developed to isolate and capture CTCs from blood samples. These technologies enable highly sensitive and specific detection of CTCs, even at very low concentrations, improving the accuracy of diagnosis and monitoring.

Furthermore, pharmaceutical companies and research institutions are increasingly investing in developing targeted therapies. CTCs are a valuable tool for drug development and clinical trials, as they can be used to assess drug efficacy, predict drug resistance, and identify potential biomarkers for patient stratification.

The COVID-19 pandemic has significantly affected the market of circulating tumor cells (CTCs). Healthcare systems worldwide experienced disruptions, leading to postponed or canceled cancer screenings, diagnoses, and treatments. Research and development efforts related to CTCs were also impacted as resources and focus shifted to COVID-19 research.

However, the pandemic brought increased attention to liquid biopsy, including the detection of CTCs, as it provides a non-invasive alternative to tissue biopsies. The demand for liquid biopsy-based CTC testing potentially rose during this time. Telemedicine and remote monitoring gained prominence, enabling healthcare professionals to remotely track CTC levels and monitor cancer patients through virtual consultations and home-based sample collection. Regulatory processes faced challenges and delays, affecting the introduction of new CTC technologies and tests.

Industry Dynamics

Growth Drivers

Empowering early cancer detection and personalized medicine

The market is experiencing growth due to the increasing prevalence of cancer worldwide necessitates effective diagnostic tools. CTCs provide valuable insights into cancer progression, aiding in early detection, treatment monitoring, and personalized medicine. As cancer cases rise, the demand for CTC-based solutions grows.

Advancements in technology play a crucial role in driving the market. Innovations in isolation, detection, and analysis methods have significantly improved the sensitivity and specificity of CTC detection. The development of platforms such as immunomagnetic separation, microfluidics, and image-based detection systems enables the identification of CTCs even at low concentrations. These technological advancements further fuel market growth.

Another significant driver is the focus on personalized medicine and targeted therapies. CTCs are instrumental in the development and evaluation of targeted treatments. They help assess drug efficacy, predict resistance, and identify biomarkers for patient stratification. With the increasing interest in precision medicine, there is a growing demand for CTC-based tests and technologies.

Report Segmentation

The market is primarily segmented based on technology, application, product, specimen, and region.

By Technology

By Application

By Product

By Specimen

By Region

  • Circulating Tumor Cells Detection & Enrichment Methods
  • Immunocapture
  • Size-based Separation
  • Density-based Separation
  • Combined Methods
  • Circulating Tumor Cells Direct Detection Methods
  • SERS
  • Microscopy
  • Others
  • Circulating Tumor Cells Analysis
  • Clinical/ Liquid Biopsy
  • Research
  • Kits & Reagents
  • Blood Collection Tubes
  • Devices or Systems
  • Blood
  • Bone Marrow
  • Other Body Fluids
  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

To Understand the Scope of this Report : Speak to Analyst

By Technology Analysis

The circulating tumor cells (CTCs) detection and enrichment method segment accounted for the largest market share in 2022

The circulating tumor cells (CTCs) detection and enrichment method segment held the largest market share. This segment involves capturing and enriching CTCs based on their biological properties. Enrichment methods can be either positive or negative based on their approach.

Positive enrichment methods aim to capture CTCs by targeting tumor-associated markers expressed in these cells. This approach allows for the selective isolation and enrichment of CTCs from the bloodstream, facilitating their detection and analysis. Positive enrichment methods are designed to capture CTCs while minimizing the capture of other blood cells or components.

By Product Analysis

Devices segment held the largest market revenue share in 2022

The devices segment of circulating tumor cells (CTCs) holds the largest revenue shares of the market. This segment focuses on developing and utilizing devices specifically designed for CTC-related applications. To enhance technical capabilities and facilitate mass production, the market has witnessed the introduction of manufactured glass microchips, which address challenges and improve overall efficiency.

Significant advances in microfluidic technology drive the growth of this segment. Microfluidics and microfabrication techniques have undergone remarkable advancements in the past decade. These innovations have applications in various fields, including chemical engineering, biotechnology, pharmaceutics, and medicine. Using microfluidic devices and systems as versatile research tools has contributed to the rapid growth of CTCs devices.

By Specimen Analysis

Blood segment hold significant market revenue shares in 2022

The blood segment holds significant market revenue shares and is likely to continue its growth during the forecast period. This segment has witnessed the highest penetration primarily because of the high concentration of CTCs in blood samples compared to other biospecimens. Blood specimens offer a rich source of CTCs, allowing for easier detection and analysis, leading to their widespread adoption in research and clinical applications.

Technological improvements have played a significant role in driving the growth of the blood segment. These advancements have effectively accelerated the identification and characterization of genomic changes among CTCs. By utilizing advanced technologies, researchers and clinicians can gain valuable insights into the genetic alterations and molecular profiles of CTCs, which are crucial for understanding tumor biology and guiding personalized treatment strategies.

Regional Insights

North America dominated the global market in 2022

The North American region has dominated the market with largest market share in the circulating tumor cells industry. This dominance can be attributed to key players in the region, including Advanced Cell Diagnostics, Aviva Biosciences, Apocell, Inc., Biocept, Inc., CellTraffix, Inc., and Biofluidica, Inc. These companies have established operations and significantly contributed to advancing CTC-related technologies and solutions, driving market growth in North America.

The rising prevalence of cancer diseases in the United States has also fueled the demand for circulating tumor cells in the region. With an increasing number of cancer cases, there is a growing need for effective diagnostic tools and treatment monitoring solutions, including CTC-based technologies. The demand for early detection, personalized medicine, and improved patient outcomes has further propelled the growth of North America's circulating tumor cells market.

Key Market Players & Competitive Insights

The increasing demand for minimally invasive cancer diagnostics and monitoring tools. Key players are at the forefront of CTC technology innovation, continually enhancing capture and analysis methods to improve sensitivity and specificity. Moreover, strategic collaborations with research institutions and healthcare providers, regulatory approvals, and clinical validations are pivotal for market growth. The global CTC market is poised for expansion, as it plays a crucial role in personalized cancer therapy and treatment monitoring, making it an attractive arena for established leaders and emerging companies in the life sciences and diagnostics sectors.

Some of the major players operating in the global market include:

  • AVIVA Biosciences
  • Bio-Techne Corporation
  • BioFluidica
  • Biolidics Limited
  • Canopus Bioscience Ltd.
  • Creativ MicroTech, Inc.
  • Epic Sciences
  • Fluxion Biosciences
  • Greiner Bio-One International GmbH
  • Ikonisys Inc
  • IVDiagnostics
  • LineaRx, Inc. (Vitatex, Inc.)
  • LungLife AI, Inc.
  • Menarini Silicon Biosystems
  • Miltenyi Biotec
  • Precision for Medicine
  • QIAGEN
  • Rarecells Diagnostics
  • ScreenCell
  • STEMCELL Technologies, Inc.
  • Sysmex Corporation

Recent Developments

  • In October 2022, Thermo Fisher has acquired The Binding Site Group. The Binding Site Group is dedicated to serving clinicians and laboratory professionals worldwide, offering a range of specialty diagnostic assays and instruments. Thermo Fisher aims to strengthen its position in the specialty diagnostics market with this strategic acquisition.
  • In February 2021, Menarini Silicon Biosystems launched the CellMag product line, a range of innovative solutions designed for manually enriching and staining rare circulating tumor cells (CTCs). The CellMag product line offers advanced technologies and techniques that facilitate the identification and analysis of CTCs, a valuable tool in cancer research and diagnosis.

Circulating Tumor Cells Market Report Scope

Report Attributes

Details

Market size value in 2024

USD 7074.1 million

Revenue forecast in 2032

USD 40,808.7 million

CAGR

13.70% from 2024 – 2032

Base year

2023

Historical data

2019 – 2022

Forecast period

2024 – 2032

Quantitative units

Revenue in USD million and CAGR from 2024 to 2032

Segments Covered

By Technology, By Application, By Product, By Specimen, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa

Customization

Report customization as per your requirements with respect to countries, region and segmentation.

FAQ's

AVIVA Biosciences,Bio-Techne Corporation,BioFluidica,Biolidics Limited,Canopus Bioscience Ltd key companies in Circulating Tumor Cells Market.

The global Circulating Tumor Cells market is expected to grow at a CAGR of 13.6% during the forecast period.

technology, application, product, specimen, and region key segments covered.

Empowering early cancer detection and personalized medicine key driving factors in Circulating Tumor Cells Market.

Circulating Tumor Cells Market Size Worth $ 40,808.7 Million By 2032